Douglas D. Taylor: Difference between revisions
Content deleted Content added
StefenTower (talk | contribs) →top: cleanup for WikiProject Louisville using AWB |
mNo edit summary |
||
| Line 3: | Line 3: | ||
Taylor attained a bachelor's degree from the [[University of Richmond]] and a Ph.D. from [[Wake Forest University]]. He was a post-doctoral fellow at [[Boston University]].<ref name="ES Board">{{Cite press release |url=http://www.prnewswire.com/news-releases/aethlon-medical-appoints-douglas-taylor-to-exosome-sciences-advisory-board-69645782.html |title=Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board |website=PR Newswire |accessdate=August 31, 2016}}</ref> Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the [[University of Louisville]] in Kentucky.<ref name="ES Board" />{{when|date=July 2015}} He was also on the faculty of the [[University of California, Davis]].<ref>{{cite web |url=http://ucdmc.ucdavis.edu/welcome/features/20080416_synthesis_tweezers/index.html |title=UC Davis Health System Feature Story: Cancer in the crosshairs |author=UC Davis Health System, Department of Public Affairs and Marketing |work=ucdavis.edu |accessdate=15 July 2015}}</ref>{{when|date=July 2015}} From 2013 to 2015, he was the Chief Scientific Officer of [[Aethlon Medical]]'s wholly owned subsidiary, [[Exosome Sciences]].<ref>{{Cite press release |url=http://www.prnewswire.com/news-releases/aethlon-medical-announces-dr-douglas-taylor-as-chief-scientific-officer-of-exosome-sciences-inc-223601621.html |title=Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc. |website=PR Newswire |accessdate=August 31, 2016}}</ref><ref>{{cite web |title=Executive Team |url=http://www.exosomesciences.com/executiveteam.aspx |website=Exosome Sciences |accessdate=March 3, 2016 |archiveurl=https://web.archive.org/web/20150817053651/http://www.exosomesciences.com/executiveteam.aspx |archivedate=August 17, 2015}}</ref> |
Taylor attained a bachelor's degree from the [[University of Richmond]] and a Ph.D. from [[Wake Forest University]]. He was a post-doctoral fellow at [[Boston University]].<ref name="ES Board">{{Cite press release |url=http://www.prnewswire.com/news-releases/aethlon-medical-appoints-douglas-taylor-to-exosome-sciences-advisory-board-69645782.html |title=Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board |website=PR Newswire |accessdate=August 31, 2016}}</ref> Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the [[University of Louisville]] in Kentucky.<ref name="ES Board" />{{when|date=July 2015}} He was also on the faculty of the [[University of California, Davis]].<ref>{{cite web |url=http://ucdmc.ucdavis.edu/welcome/features/20080416_synthesis_tweezers/index.html |title=UC Davis Health System Feature Story: Cancer in the crosshairs |author=UC Davis Health System, Department of Public Affairs and Marketing |work=ucdavis.edu |accessdate=15 July 2015}}</ref>{{when|date=July 2015}} From 2013 to 2015, he was the Chief Scientific Officer of [[Aethlon Medical]]'s wholly owned subsidiary, [[Exosome Sciences]].<ref>{{Cite press release |url=http://www.prnewswire.com/news-releases/aethlon-medical-announces-dr-douglas-taylor-as-chief-scientific-officer-of-exosome-sciences-inc-223601621.html |title=Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc. |website=PR Newswire |accessdate=August 31, 2016}}</ref><ref>{{cite web |title=Executive Team |url=http://www.exosomesciences.com/executiveteam.aspx |website=Exosome Sciences |accessdate=March 3, 2016 |archiveurl=https://web.archive.org/web/20150817053651/http://www.exosomesciences.com/executiveteam.aspx |archivedate=August 17, 2015}}</ref> |
||
Taylor first described [[exosome (vesicle)|exosomes]] in the 1980s, originally believing them to be cell fragments.<ref>[https://books.google.com/books?id=nv3R3U3kwO8C&pg=PA843&lpg=PA843&dq=Douglas+Taylor+cancer&source=bl&ots=hzN5FkXdTa&sig=GO1DJRvAQphD12W2v3jBUSlrFXA&hl=en&sa=X&ved=0CCoQ6AEwAjgeahUKEwi41ryExdjGAhWDD5IKHVPCCYE#v=onepage&q=Douglas%20Taylor%20cancer&f=false Todd S. Ing, et al, ''Dialysis: History, Development and Promise'' (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843]</ref> He later wrote that exosomes could potentially be used as [[biomarker]]s for profiling in [[ovarian cancer]] biopsies, and could extend their utility to screening other asymptomatic areas.<ref>{{cite journal |last1=Taylor |first1=Douglas |title=MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer |journal=Gynecologic Oncology |date=July 2008 |volume=110 |issue=1 |pages=13–21 |doi=10.1016/j.ygyno.2008.04.033 |pmid=18589210}}</ref> |
Taylor first described [[exosome (vesicle)|exosomes]] in the 1980s, originally believing them to be cell fragments.<ref>[https://books.google.com/books?id=nv3R3U3kwO8C&pg=PA843&lpg=PA843&dq=Douglas+Taylor+cancer&source=bl&ots=hzN5FkXdTa&sig=GO1DJRvAQphD12W2v3jBUSlrFXA&hl=en&sa=X&ved=0CCoQ6AEwAjgeahUKEwi41ryExdjGAhWDD5IKHVPCCYE#v=onepage&q=Douglas%20Taylor%20cancer&f=false Todd S. Ing, et al, ''Dialysis: History, Development and Promise'' (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843]</ref> He later wrote that exosomes could potentially be used as [[biomarker]]s for profiling in [[ovarian cancer]] biopsies, and could extend their utility to screening other asymptomatic areas.<ref>{{cite journal |last1=Taylor |first1=Douglas |title=MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer |journal=Gynecologic Oncology |date=July 2008 |volume=110 |issue=1 |pages=13–21 |doi=10.1016/j.ygyno.2008.04.033 |pmid=18589210}}</ref> What constitues exosomes has not been defined; specifically, markers of exosomes are abstractly defined. <ref>{{cite journal|last1=Edgar|first1=James|title=Q&A: What are exosomes, exactly?|journal=BMC Biology|date=2016|volume=14|issue=1|pmid=27296830}}</ref> |
||
In 2015, the ''[[Journal of Immunology]]'' retracted a paper it published in 2006 and which Taylor had co-written<ref>{{cite journal | pmid = 16424182 | volume=176 | title=Pregnancy-associated exosomes and their modulation of T cell signaling | journal=J Immunol | pages=1534–42 | last1 = Taylor | first1 = DD | last2 = Akyol | first2 = S | last3 = Gercel-Taylor | first3 = C | doi=10.4049/jimmunol.176.3.1534}}</ref> after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".<ref>[http://www.jimmunol.org/content/194/12/6190.full "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling,"] ''Journal of Immunology'', June 15, 2015, vol. 194 no. 12 6190.{{subscription required}}</ref><ref name="Retraction Watch">{{cite web |last1=Bernès |first1=Sylvain |title=Exosome pioneer's paper retracted after investigation finds "multiple" faked figures |url=http://retractionwatch.com/2015/06/10/exosome-pioneers-paper-retracted-after-investigation-finds-multiple-falsified-figures/ |website=[[Retraction Watch]] |accessdate=January 7, 2016 |date=June 10, 2015}}</ref> Taylor responded to the retraction on the blog [[Retraction Watch]], disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".<ref name="Retraction Watch" /> |
In 2015, the ''[[Journal of Immunology]]'' retracted a paper it published in 2006 and which Taylor had co-written<ref>{{cite journal | pmid = 16424182 | volume=176 | title=Pregnancy-associated exosomes and their modulation of T cell signaling | journal=J Immunol | pages=1534–42 | last1 = Taylor | first1 = DD | last2 = Akyol | first2 = S | last3 = Gercel-Taylor | first3 = C | doi=10.4049/jimmunol.176.3.1534}}</ref> after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".<ref>[http://www.jimmunol.org/content/194/12/6190.full "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling,"] ''Journal of Immunology'', June 15, 2015, vol. 194 no. 12 6190.{{subscription required}}</ref><ref name="Retraction Watch">{{cite web |last1=Bernès |first1=Sylvain |title=Exosome pioneer's paper retracted after investigation finds "multiple" faked figures |url=http://retractionwatch.com/2015/06/10/exosome-pioneers-paper-retracted-after-investigation-finds-multiple-falsified-figures/ |website=[[Retraction Watch]] |accessdate=January 7, 2016 |date=June 10, 2015}}</ref> Taylor responded to the retraction on the blog [[Retraction Watch]], disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".<ref name="Retraction Watch" /> |
||
Revision as of 05:25, 26 May 2017
Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.
Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University.[1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky.[1][when?] He was also on the faculty of the University of California, Davis.[2][when?] From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences.[3][4]
Taylor first described exosomes in the 1980s, originally believing them to be cell fragments.[5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas.[6] What constitues exosomes has not been defined; specifically, markers of exosomes are abstractly defined. [7]
In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written[8] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".[9][10] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".[10]
References
- ^ a b "Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board". PR Newswire (Press release). Retrieved August 31, 2016.
- ^ UC Davis Health System, Department of Public Affairs and Marketing. "UC Davis Health System Feature Story: Cancer in the crosshairs". ucdavis.edu. Retrieved 15 July 2015.
- ^ "Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc". PR Newswire (Press release). Retrieved August 31, 2016.
- ^ "Executive Team". Exosome Sciences. Archived from the original on August 17, 2015. Retrieved March 3, 2016.
- ^ Todd S. Ing, et al, Dialysis: History, Development and Promise (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843
- ^ Taylor, Douglas (July 2008). "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer". Gynecologic Oncology. 110 (1): 13–21. doi:10.1016/j.ygyno.2008.04.033. PMID 18589210.
- ^ Edgar, James (2016). "Q&A: What are exosomes, exactly?". BMC Biology. 14 (1). PMID 27296830.
- ^ Taylor, DD; Akyol, S; Gercel-Taylor, C. "Pregnancy-associated exosomes and their modulation of T cell signaling". J Immunol. 176: 1534–42. doi:10.4049/jimmunol.176.3.1534. PMID 16424182.
- ^ "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," Journal of Immunology, June 15, 2015, vol. 194 no. 12 6190.(subscription required)
- ^ a b Bernès, Sylvain (June 10, 2015). "Exosome pioneer's paper retracted after investigation finds "multiple" faked figures". Retraction Watch. Retrieved January 7, 2016.